Cardurion Pharmaceuticals

Cardurion Pharmaceuticals

Verified
Translating the science of cardiac myocyte signaling pathways into groundbreaking therapeutics. Learn more

Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$1.2—1.8b (Dealroom.co estimates Oct 2021.)
Boston Massachusetts (HQ)
  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

$15.7m

Debt

$10.0m

-

$300m

Early VC
*
N/A

$17.5m

Debt
Total Funding$310m

Recent News about Cardurion Pharmaceuticals

Edit
More about Cardurion Pharmaceuticals
Edit

Cardurion Pharmaceuticals is a biotechnology startup that operates in the healthcare sector, specifically in the development of innovative cardiovascular medicines. The company's primary focus is on groundbreaking clinical programs in PDE9 and CaMKII inhibition. In simpler terms, Cardurion is working on creating drugs that can inhibit or block certain enzymes (PDE9 and CaMKII) in the body, which are believed to play a significant role in heart diseases.

The company's clients are primarily healthcare providers and patients suffering from cardiovascular diseases. By developing novel treatments, Cardurion aims to address the unmet medical needs in the cardiovascular disease market, which is one of the leading causes of death globally.

Cardurion's business model revolves around research and development (R&D), clinical trials, and commercialization of their drugs. The company invests heavily in R&D to discover and develop potential treatments. Once a drug shows promise, it undergoes rigorous clinical trials to test its safety and effectiveness. If the drug passes these trials, it is then commercialized and sold to healthcare providers. The revenue is generated from the sales of these drugs.

In summary, Cardurion Pharmaceuticals is a promising startup in the biotech sector, focusing on the development of innovative treatments for cardiovascular diseases. It operates in a high-demand market and has a business model centered around the research, development, and commercialization of novel drugs.

Keywords: Cardurion Pharmaceuticals, Biotechnology, Healthcare, Cardiovascular Diseases, PDE9 Inhibition, CaMKII Inhibition, Drug Development, Clinical Trials, Research and Development, Commercialization.